



BC Centre for Disease Control
Provincial Health Services Authority

Immunization Programs and Vaccine Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: August 1, 2023

Administrative Circular: 2023:22

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

The following updates have been made:

- The monovalent Pfizer COVID-19 mRNA vaccine for adults/adolescents was removed from the eligibility table as this product is no longer available.
- A footnote indicating the minimum interval between doses in the primary series for monovalent Moderna COVID-19 mRNA vaccine for 6 years of age and older was removed.
- Footnote G on page 2 has been updated to indicate “Individuals presenting for a Spring 2023 booster dose now should be counselled that this will likely delay receipt of a fall 2023 booster dose, given the recommended 6 month interval between booster doses.”

Please remove page numbers: 1-3 dated June 2023
Please add new page numbers: 1-3 dated August 2023

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) Adult/Adolescent

This product page has been removed from the BC Immunization Manual as all lots of this formulation have expired.

Please remove page numbers: 1-5 dated June 2023

Page 1 of 3

COVID-19 Vaccine NUVAXOVID™ (Novavax)

- Content related to stability of the vaccine following first vial puncture and length of time vaccine can be pre-loaded into a syringe has been updated under ADMINISTRATION to align with recent changes to the product monograph. After first vial puncture, the vaccine is stable at +2°C to +8°C for 12 hours or at room temperature (up to +25°C) for 6 hours.
- Content under ADVERSE EVENTS has been updated to include rates of myocarditis/pericarditis following receipt of Novavax COVID-19 vaccine.

Please remove page numbers: 1-3 dated May 2023
Please add new page numbers: 1-3 dated August 2023

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated June 2023 and replace with the enclosed updated Title Page and Table of Contents dated August 2023.

The [COVID-19 Vaccination Schedule Infographic](#) and the [COVID-19 mRNA Vaccine Comparison Table](#) have been updated to remove the monovalent Pfizer mRNA COVID-19 Adult/Adolescent vaccine. Both resources can be found on the [COVID-19 vaccination toolkit for health professionals](#).

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Communicable Disease Prevention and Control,
Population & Public Health Division:

Bethany McMullen
Director, Immunizations

Brian Sagar
A/Executive Director